Hammer SM, Squires KE, Hughes MD.
et al. for the AIDS Clinical Trials Group 320 Study Team. A controlled trial of two nucleoside analogues plus indinavir in persons
with human immunodeficiency virus infection and CD4 cell counts of 200 per
cubic millimeter or less. N Engl J Med.1997;337:725-733.
Gulick RM, Mellors JW, Havlir D.
et al. Treatment with indinavir, zidovudine, and lamivudine in adults with
human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med.1997;337:734-739.
Perelson AS, Essunger P, Cao Y.
et al. Decay characteristics of HIV-1-infected compartments during combination
Luzuriaga K, Bryson Y, Krogstad P.
et al. Combination treatment with zidovudine, didanosine, and nevirapine in
infants with human immunodeficiency virus type 1 infection. N Engl J Med.1997;336:1343-1349.
Luzuriaga K, Wu H, McManus M.
et al. Dynamics of human immunodeficiency virus type 1 replication in vertically
infected infants. J Virol.1999;73:362-367.
Melvin AJ, Rodrigo AG, Mohan KM.
et al. HIV-1 dynamics in children. J Acquir Immune Defic Syndr Hum Retrovirol.1999;20:468-473.
Havlir DV, Hellmann NS, Petropoulos CJ.
et al. Drug susceptibility in HIV infection after viral rebound in patients
receiving indinavir-containing regimens. JAMA.2000;283:229-234.
Descamps D, Flandre P, Calvez V.
et al. for the Trilege (Agence Nationale de Recherches sur le SIDA 072) Study
Team. Mechanisms of virologic failure in previously untreated HIV-infected
patients from a trial of induction-maintenance therapy. JAMA.2000;283:205-211.
Hirsch MS, Brun-Vezinet F, D'Aquila RT.
et al. Antiretroviral drug resistance testing in adult HIV-1 infection. JAMA.2000;283:2417-2426.
Zhang L, Ramratnam B, Tenner-Racz K.
et al. Quantifying residual HIV-1 replication in patients receiving combination
antiretroviral therapy. N Engl J Med.1999;340:1605-1613.
Furtado MR, Callaway DS, Phair JP.
et al. Persistence of HIV-1 transcription in peripheral blood mononuclear
cells in patients receiving potent antiretroviral therapy. N Engl J Med.1999;340:1614-1622.
Dornadula G, Zhang H, VanUitert B.
et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly
active antiretroviral therapy. JAMA.1999;282:1627-1632.
Chun TW, Stuyver L, Mizell SB.
et al. Presence of an inducible HIV-1 latent reservoir during highly active
antiretroviral therapy. Proc Natl Acad Sci U S A.1997;94:13193-13197.
Grossman Z, Feinberg M, Kuznetsov V.
et al. HIV infection: how effective is drug combination treatment? Immunol Today.1998;19:528-532.
Sharkey ME, Teo I, Greenough T.
et al. Persistence of episomal HIV-1 infection intermediates in patients on
highly active anti-retroviral therapy. Nat Med.2000;6:76-81.
Yerly S, Kaiser L, Perneger TV.
et al. for the Swiss HIV Cohort Study. Time of initiation of antiretroviral therapy: impact on HIV-1 viraemia. AIDS.2000;14:243-249.
Ramratnam B, Mittler JE, Zhang L.
et al. The decay of the latent reservoir of replication-competent HIV-1 is
inversely correlated with the extent of residual viral replication during
prolonged anti-retroviral therapy. Nat Med.2000;6:82-85.
Gunthard HF, Wong JK, Ignacio CC.
et al. Human immunodeficiency virus replication and genotypic resistance in
blood and lymph nodes after a year of potent antiretroviral therapy. J Virol.1998;72:2422-2428.
Chun TW, Finzi D, Margolick J.
et al. In vivo fate of HIV-1-infected T cells: quantitative analysis of the
transition to stable latency. Nat Med.1995;1:1284-1290.
Chun TW, Carruth L, Finzi D.
et al. Quantitation of latent tissue reservoirs and total body viral load
in HIV-1 infection. Nature.1997;387:183-188.
Finzi D, Hermankova M, Pierson T.
et al. Identification of a reservoir for HIV-1 in patients on highly active
antiretroviral therapy. Science.1997;278:1295-1300.
Wong JK, Hezareh M, Gunthard HF.
et al. Recovery of replication-competent HIV despite prolonged suppression
of plasma viremia. Science.1997;278:1291-1295.
Finzi D, Blankson J, Siliciano JD.
et al. Latent infection of CD4+ T cells provides a mechanism for lifelong
persistence of HIV-1, even in patients on effective combination therapy. Nat Med.1999;5:512-517.
Persaud D, Pierson T, Ruff C.
et al. A stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes
in infected children. J Clin Invest.2000;105:995-1003.
Learn Jr GH, Korber BT, Foley B.
et al. Maintaining the integrity of human immunodeficiency virus sequence
databases. J Virol.1996;70:5720-5730.
Smith DB, McAllister J, Casino C, Simmonds P. Virus "quasispecies": making a mountain out of a molehill? J Gen Virol.1997;78(pt 7):1511-1519.
Swofford DL. PAUP*, Phylogenetic Analysis Using Parsimony (*And
Other Methods). Version 4. Sunderland, Mass: Sinauer; 2000.
Saitou N, Nei M. The neighbor-joining method: a new method for reconstructing phylogenetic
trees. Mol Biol Evol.1987;4:406-425.
Felsenstein J. Confidence limits on phylogenies: an approach using the bootstrap. Evolution.1985;39:783-791.
Martinez-Picado J, Kartsonis N, Hanna GJ.
et al. Antiretroviral resistance during successful therapy of human immunodeficiency
virus type 1 infection. Proc Natl Acad Sci U S A.2000;97:10948-10953.
Schinazi RF, Lloyd Jr RM, Nguyen MH.
et al. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine
nucleosides. Antimicrob Agents Chemother.1993;37:875-881.
Tisdale M, Kemp SD, Parry NR, Larder BA. Rapid in vitro selection of human immunodeficiency virus type 1 resistant
to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse
transcriptase. Proc Natl Acad Sci U S A.1993;90:5653-5656.
Hertogs K, Bloor S, DeVroey V.
et al. A novel human immunodeficiency virus type 1 reverse transcriptase mutational
pattern confers phenotypic lamivudine resistance in the absence of mutation
184V. Antimicrob Agents Chemother.2000;44:568-573.
Richman DD, Havlir D, Corbeil J.
et al. Nevirapine resistance mutations of human immunodeficiency virus type
1 selected during therapy. J Virol.1994;68:1660-1666.
Demeter LM, Shafer RW, Meehan PM.
et al. Delavirdine susceptibilities and associated reverse transcriptase mutations
in human immunodeficiency virus type 1 isolates from patients in a phase I/II
trial of delavirdine monotherapy (ACTG 260). Antimicrob Agents Chemother.2000;44:794-797.
Patick AK, Duran M, Cao Y.
et al. Genotypic and phenotypic characterization of human immunodeficiency
virus type 1 variants isolated from patients treated with the protease inhibitor
nelfinavir. Antimicrob Agents Chemother.1998;42:2637-2644.
Atkinson B, Isaacson J, Knowles M.
et al. Correlation between human immunodeficiency virus genotypic resistance
and virologic response in patients receiving nelfinavir monotherapy or nelfinavir
with lamivudine and zidovudine. J Infect Dis.2000;182:420-427.
Molla A, Korneyeva M, Gao Q.
et al. Ordered accumulation of mutations in HIV protease confers resistance
to ritonavir. Nat Med.1996;2:760-766.
de Mendoza C, Soriano V, Briones C.
et al. Emergence of zidovudine resistance in HIV-infected patients receiving
stavudine. J Acquir Immune Defic Syndr.2000;23:279-281.
Winters MA, Coolley KL, Girard YA.
et al. A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency
virus type 1 confers resistance to multiple nucleoside inhibitors. J Clin Invest.1998;102:1769-1775.
Markowitz M, Mo H, Kempf DJ.
et al. Selection and analysis of human immunodeficiency virus type 1 variants
with increased resistance to ABT-538, a novel protease inhibitor. J Virol.1995;69:701-706.
Gunthard HF, Frost SD, Leigh-Brown AJ.
et al. Evolution of envelope sequences of human immunodeficiency virus type
1 in cellular reservoirs in the setting of potent antiviral therapy. J Virol.1999;73:9404-9412.
Ho DD, Zhang L. HIV-1 rebound after anti-retroviral therapy. Nat Med.2000;6:736-737.
Chun TW, Davey Jr RT, Ostrowski M.
et al. Relationship between pre-existing viral reservoirs and the re-emergence
of plasma viremia after discontinuation of highly active anti-retroviral therapy. Nat Med.2000;6:757-761.
Imamichi H, Crandall KA, Natarajan V.
et al. Human immunodeficiency virus type 1 quasi species that rebound after
discontinuation of highly active antiretroviral therapy are similar to the
viral quasi species present before initiation of therapy. J Infect Dis.2001;183:36-50.
Brown AJ, Richman DD. HIV-1: gambling on the evolution of drug resistance? Nat Med.1997;3:268-271.
Rouzine IM, Coffin JM. Linkage disequilibrium test implies a large effective population number
for HIV in vivo. Proc Natl Acad Sci U S A.1999;96:10758-10763.